PD-L1 expressing epithelial ovarian carcinoma

PD-L1 expressing epithelial ovarian carcinoma refers to a malignant neoplasm arising from the ovarian surface epithelium or distal fallopian tube that demonstrates immunohistochemical detection of programmed death-ligand 1 on tumor or tumor-infiltrating immune cells Identifying PD-L1 expression serves as a biomarker-defined clinical state that delineates an immunologically active subset of epithelial ovarian cancer potentially susceptible to immune checkpoint inhibitor therapies

PD-L1 expressing epithelial ovarian carcinoma refers to a malignant neoplasm arising from the ovarian surface epithelium or distal fallopian tube that demonstrates immunohistochemical detection of programmed death-ligand 1 on tumor or tumor-infiltrating immune cells Biologically, the presence of cell-surface PD-L1 promotes local immune tolerance by binding PD-1 receptors on cytotoxic T lymphocytes to attenuate antitumor immune surveillance within the tumor microenvironment

PD-L1 expressing epithelial ovarian carcinoma refers to a malignant neoplasm arising from the ovarian surface epithelium or distal fallopian tube that demonstrates immunohistochemical detection of programmed death-ligand 1 on tumor or tumor-infiltrating immune cells

This gynecologic malignancy is characterized pathologically by cellular atypia, invasion into the pelvic and peritoneal cavities, and often high rates of recurrence or chemotherapy resistance

Biologically, the presence of cell-surface PD-L1 promotes local immune tolerance by binding PD-1 receptors on cytotoxic T lymphocytes to attenuate antitumor immune surveillance within the tumor microenvironment

Identifying PD-L1 expression serves as a biomarker-defined clinical state that delineates an immunologically active subset of epithelial ovarian cancer potentially susceptible to immune checkpoint inhibitor therapies